DOCSLIB.ORG

Diabetes As Autoimmune Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Diabetes As Autoimmune Disease 14th EFLM Continuous Postgraduate Course in Clinical Chemistry and Laboratory Medicine Diabetes as autoimmune disease - manifested T1D is based traditionally on diabetes Diabetes type I mellitus typical clinical symptoms: polyuria, in- creased thirst, weight loss, weakness, hunger, re- current infection and in severe insulinopenia the Evgenija Homsak patient are prone to diabetic ketoacidosis . Impor- Department for Laboratory Diagnostics, University Clinical tant diagnostic parameters are also for T1D char- Centre Maribor, Maribor, Slovenia acteristic HLA gene and especially different auto- antibodies against antigens of β cells, which could Corresponding author: evgenija .homsak@ukc-mb .si be present several years before clinical manifesta- tion of disease . Introduction Type 1 diabetes mellitus (T1D), also known as insu- Pathogenesis lin - dependent diabetes mellitus, is a chronic im- T1D is an autoimmune disorder against the β cells mune mediated disease that is characterized by of the pancreatic islets, that remain only 10-20% selective loss of insulin producing β cells of the functioning at the time of diagnosis . For T1D is pancreatic islets in genetically susceptible sub- characteristic subclinical prodrome of variable du- jects . The majority (95%) of cases are attributable ration, as the pathogenetic process begins years to an autoimmune-mediated destruction of β cells before the clinical onset, when the tolerance to (type 1a) while a small minority (5%) of cases re- self-autoantigens is lost (5) . The whole process and sults from an idiopathic destruction or failure of β factors that contribute to and influence the de- cells (type 1b) (1) . T1D is observed in approximate- struction of the β cells is still not known . Still limit- ly 5-10% of diabetes mellitus patient . It may be ed current knowledge of pathogenesis of T1D as present at any age and with equal affection of autoimmune disease is based on several impor- both sexes . It appears most typically in early life tant known facts, which have been gained with a peak around the puberty, but one-fourth of through several studies, mostly using animal mod- cases are diagnosed in adults . T1D remains the els and confirmed by human clinical trials . This most common form of diabetes in childhood, ac- process occurs in genetically susceptible subjects, counting for approximately two-thirds of new di- is probably triggered by one or more environmen- agnoses of diabetes in patients ≤19 years of age in tal agents, and usually progresses over many the United States, despite the increasing rate of months or years during which the subject is type 2 diabetes . The incidence of T1D varies 50- asymptomatic and euglycemic . Important genetic 100 fold around the world, with the highest rates predisposition in the presence of not yet defined in northern Europe, with 57 4. cases/100 0. 00 per triggers and modulators from the environment year in Finland and with relatively low incidence of could influence on modulation of immune system 0 6. /100 0. 00 in China (2) . The incidence of child- to lose the tolerance to auto-antigens and results hood T1D is rising rapidly in all population, espe- with several autoimmune reactions, local inflam- cially in the age under 5 years, that suggests a mation (insulitis), specific T cell (LyT) and B cell strong environmental contribution . Lately, (LyB) responses, autoantibody production, and cell through several studies, there are strong efforts to destructions . The proposed mechanism of autoim- understand and explain pathogenesis and find mune inflammation process start with presenta- the new therapeutic options of the disease ac- tion of self antigens on antigen presenting cells cording to potential auto-antigens (insulin) and (dendritic, LyB, macrophage), that after releasing different environmental factors, as an important interleukin (IL)-12 activate LyT (CD4 T) that produce key in the development of T1D . But the role of spe- important key cytokine INF-γ . They inhibit Th2 cy- cific factors such as viruses or ingested food (milk) tokine production, enhance production of toxic remains controversial (3,4) . Diagnosis of clinical cytokine (IL-β, TNF-α) and free radical by mac- Biochemia Medica 2014;24(Suppl 1):S1-S78 S35 Supplement.indd 35 20.10.2014. 8:44:04 14th EFLM Continuous Postgraduate Course in Clinical Chemistry and Laboratory Medicine rophage, and activate cytotoxic CD8T cells that af- ulation is important for predicting disease, accura- fects the β cells . Important connection between cy of diagnosis, prognosis and treatment . LyT and LyB causes activation of LyB for produc- LyT and LyB involvement: Autoimmunity and in- tion of auto-antibodies . Auto-antibodies, several volvement of LyT is further supported with the cytokines, cytotoxic CD8T cells with releasing per- presence of specific LyT infiltrates within inflamed forine, granzymes or by Fas-mediated apoptosis islets of pancreas of patient with T1D, according to affect and progressively destroy the β cells . Addi- Imagawa and co-workers, who found close corre- tionally local chemokine production attracts auto- lation between serological and histological mark- reactive lymphocytes that potentiate the destruc- ers and histological evidence of cellular autoim- tive autoimmune process . (4,5,6) In pathogenesis munity (10) . Insulitis as autoimmune inflammation of T1D we could find some similarities with other could be present years before hyperglycemia is autoimmune diseases, like celiac disease; the com- evident . Ly B cells also serve as antigen presenting mon genetic susceptibility, unknown hypothetical cells and as autoantibodies producing cells (6) . trigger from environment, infection, driving auto- Both Ly as important actors of disease could be antigen, autoantibodies and outcome (1/5 of with target of the future therapeutic options . HLA conferred susceptibility progresses to clinical disease) . Autoantibodies: There are five disease related autoantibodies: islet cell antibodies (ICA), insulin Genetics: Disease susceptibility is highly associat- autoantibodies (IAA) with epitope on B-chain of ed with the inheritance or presence of certain hu- insulin molecule, autoantibodies against 65-kDa man leukocyte antigen (HLA), which is characteris- isoform of glutamic acid decarboxilase (GAD65), tic for autoimmune diseases . HLA molecules are tyrosine phosphatase related IA-2 molecule or in- responsible for presentation of peptides (also au- sulinoma associate antigen-2 antibodies (IA-2) and to-antigens) to Ly T cells and are involved in thym- zinc transporter protein (ZnT8) . Presence of auto- ic selection of new generated T cell repertoire antibodies are evident years before clinical onset (central tolerance), to avoid potential autoimmune and are mostly the first sign of autoimmune pro- clones that could be released into the periphery . cess, that will or not progress to T1D . Several stud- Therefore, a defect within the thymus or presence ies confirm their important role in prediction of of specific HLA molecules allows autoimmune T the disease development and appearance accord- cells to escape central tolerance . HLA genes on ing to the detection of different specific autoanti- short arm of chromosome 6p21 3. with alleles DR3 bodies (4,5,11) . Mrena and co-workers in the Finn- and DR4 as well as the associated alleles DQ2 and ish DIPP study observed that presence of positivity DQ8, that are expressed either as DR3DQ2 or for only a single autoantibody specificity for sev- DR4DQ8, are present in more than 90% of individ- uals with T1D (7) . Remain 10% of T1D might have eral years represents in most cases harmless non- influence of 20 non-HLA genes . Among them are progresive β cell autoimmunity, whereas the pres- important polymorphisms on insulin locus on ence of two or more autoantibodies reflects a pro- chromosome 11p5,5 (PTPN22 and INS VNTR) that gressive process (10) . But their direct pathogenetic contributes approximately 10% to the familial ag- role is controversial, since transfer of autoantibod- gregation of disease (8) . As with HLA, peripheral T ies, using serum of diabetic humans, alone did not cell repertoires may be significantly influenced by reconstitute disease and that plasmapheresis pro- polymorphisms in the insulin gene affecting thy- vides little therapeutic benefit (6,12) . mocyte selection . Recent studies identifies auto- Environment factors as a triggers and drivers immune disease associated polymorphisms of T of disease: There is still unexplained cause of ini- cell regulatory gene CTLA-4 (chromosome 2q22), tiation of the autoimmune process and why the that reduce the efficiency of regulatory function of auto-antigens become auto-antigenic . The factors LyT4CD4 cells (9) . Understanding the genetics of that control progression from insulitis (inflamma- T1D as well the determination of susceptible pop- tion of the β cells) to diabetes remain largely un- Biochemia Medica 2014;24(Suppl 1):S1-S78 S36 Supplement.indd 36 20.10.2014. 8:44:04 14th EFLM Continuous Postgraduate Course in Clinical Chemistry and Laboratory Medicine known . Understanding this may provide new op- Thus, genetic markers for T1D are present from portunities for preventing disease among popula- birth, immune markers are detectable after the tion with high risk for developing T1D or halt pro- onset of the autoimmune process, and metabolic gression of the β cells lost . markers can be detected with sensitive tests once There are recently several approaches for pre- enough β cell
Load more

Recommended publications
  • Vaccination and Autoimmune Disease: What Is the Evidence?
    REVIEW Review Vaccination and autoimmune disease: what is the evidence? David C Wraith, Michel Goldman, Paul-Henri Lambert As many as one in 20 people in Europe and North America have some form of autoimmune disease. These diseases arise in genetically predisposed individuals but require an environmental trigger. Of the many potential environmental factors, infections are the most likely cause. Microbial antigens can induce cross-reactive immune responses against self-antigens, whereas infections can non-specifically enhance their presentation to the immune system. The immune system uses fail-safe mechanisms to suppress infection-associated tissue damage and thus limits autoimmune responses. The association between infection and autoimmune disease has, however, stimulated a debate as to whether such diseases might also be triggered by vaccines. Indeed there are numerous claims and counter claims relating to such a risk. Here we review the mechanisms involved in the induction of autoimmunity and assess the implications for vaccination in human beings. Autoimmune diseases affect about 5% of individuals in Autoimmune disease and infection developed countries.1 Although the prevalence of most Human beings have a highly complex immune system autoimmune diseases is quite low, their individual that evolved from the fairly simple system found in incidence has greatly increased over the past few years, as invertebrates. The so-called innate invertebrate immune documented for type 1 diabetes2,3 and multiple sclerosis.4 system responds non-specifically to infection, does not Several autoimmune disorders arise in individuals in age- involve lymphocytes, and hence does not display groups that are often selected as targets for vaccination memory.
    [Show full text]
  • Type 1 Diabetes and Celiac Disease: Overview and Medical Nutrition Therapy
    Nutrition FYI Type 1 Diabetes and Celiac Disease: Overview and Medical Nutrition Therapy Sarah Jane Schwarzenberg, MD, and Carol Brunzell, RD, CDE In patients with celiac disease (gluten- problems recognized only retrospec- glycemia, but only several months sensitive enteropathy, or GSE), inges- tively as resulting from celiac disease; after initiation. tion of the gliadin fraction of wheat it is common for “asymptomatic” It seems likely that a malabsorp- gluten and similar molecules (pro- patients to report improved health or tive disease could create opportunity lamins) from barley, rye, and possibly sense of well-being when following a for hypoglycemia in diabetes, partic- oats causes damage to the intestinal gluten-free diet. Up to one-third of ularly in patients under tight control. epithelium. The injury results from an patients may have unexplained failure Serological testing for GSE in abnormal T-cell response against to thrive, abdominal pain, or short patients with type 1 diabetes, with gliadin. Thus, GSE is a disease in stature.3,6 early diagnosis of GSE, may reduce which host susceptibility must be More controversial is the question this risk by allowing patients to be combined with a specific environmen- of whether GSE affects blood glucose diagnosed in a pre-symptomatic tal trigger to affect injury.1 control. A study by Acerini et al.7 in a state. It also seems prudent to closely Typically, patients with GSE have type 1 diabetic population found no monitor insulin needs and blood glu- chronic diarrhea and failure to thrive. difference between the celiac and non- cose control during the early phase of However, some patients present with celiac subpopulation in terms of instituting a gluten-free diet.
    [Show full text]
  • Conditions Related to Inflammatory Arthritis
    Conditions Related to Inflammatory Arthritis There are many conditions related to inflammatory arthritis. Some exhibit symptoms similar to those of inflammatory arthritis, some are autoimmune disorders that result from inflammatory arthritis, and some occur in conjunction with inflammatory arthritis. Related conditions are listed for information purposes only. • Adhesive capsulitis – also known as “frozen shoulder,” the connective tissue surrounding the joint becomes stiff and inflamed causing extreme pain and greatly restricting movement. • Adult onset Still’s disease – a form of arthritis characterized by high spiking fevers and a salmon- colored rash. Still’s disease is more common in children. • Caplan’s syndrome – an inflammation and scarring of the lungs in people with rheumatoid arthritis who have exposure to coal dust, as in a mine. • Celiac disease – an autoimmune disorder of the small intestine that causes malabsorption of nutrients and can eventually cause osteopenia or osteoporosis. • Dermatomyositis – a connective tissue disease characterized by inflammation of the muscles and the skin. The condition is believed to be caused either by viral infection or an autoimmune reaction. • Diabetic finger sclerosis – a complication of diabetes, causing a hardening of the skin and connective tissue in the fingers, thus causing stiffness. • Duchenne muscular dystrophy – one of the most prevalent types of muscular dystrophy, characterized by rapid muscle degeneration. • Dupuytren’s contracture – an abnormal thickening of tissues in the palm and fingers that can cause the fingers to curl. • Eosinophilic fasciitis (Shulman’s syndrome) – a condition in which the muscle tissue underneath the skin becomes swollen and thick. People with eosinophilic fasciitis have a buildup of eosinophils—a type of white blood cell—in the affected tissue.
    [Show full text]
  • The Saga of Antigen-Specific Immunotherapy for Type 1 Diabetes
    Diabetes Volume 70, June 2021 1247 The SAgA of Antigen-Specific Immunotherapy for Type 1 Diabetes Roberto Mallone1,2 and Sylvaine You1 Diabetes 2021;70:1247–1249 | https://doi.org/10.2337/dbi21-0011 1 Islet antigen-specific strategies are the holy grail of genic BDC2.5 CD4 T cells (8), or with its more potent immunotherapy for type 1 diabetes (T1D) (1), as they se- p79 mimotope. Contrary to free peptides, these SAgAs ef- lectively target the autoimmune responses involved in ficiently prevented diabetes in NOD mice only when used b-cell destruction (2). The idea is to induce a response op- in combination. While this may reflect the need to posite to that of a conventional vaccine. The administra- achieve a critical quantitative threshold of T cells targeted, tion of antigen(s) in the absence of inflammation (e.g., a synergistic functional effect is plausible. Indeed, 2.5HIP- adjuvants) should potentiate the outcomes of physiological reactive and p79-reactive T cells, which were, surprisingly, immune homeostasis, i.e., anergy, regulatory polarization, distinct populations, underwent different outcomes upon 1 and, to a lesser extent, deletion. Such antigens can be de- treatment with their cognate SAgA (Fig. 1). IL-10 Treg- livered as proteins, peptides, bacteria engineered to secrete ulatory (Tr)1 cells were induced by the more potent p79 1 these products, DNA plasmids, or nanoparticles coated ligand, while Foxp3 Tregs were amplified, but not de with antigens (either alone or preloaded on MHC mole- novo induced, by the weaker (and less soluble) 2.5HIP. COMMENTARY cules). Peptides are easy to synthesize by amino acid These effects were dose-dependent, as SAgAs induced Tr1 1 chemistry, but they are variably water-soluble and short- cells at higher dose and Foxp3 Tregs at lower dose.
    [Show full text]
  • African Americans and Lupus
    African Americans QUICK GUIDE and Lupus 1 Facts about lupus n People of all races and ethnic groups can develop lupus. n Women develop lupus much more often than men: nine of every 10 It is not people with lupus are women. Children can develop lupus, too. known why n Lupus is three times more common in African American women than lupus is more in Caucasian women. common n As many as 1 in 250 African American women will develop lupus. in African Americans. n Lupus is more common, occurs at a younger age, and is more severe in African Americans. Some scientists n It is not known why lupus is more common in African Americans. Some scientists think that it is related to genes, but we know that think that it hormones and environmental factors play a role in who develops is related to lupus. There is a lot of research being done in this area, so contact the genes, but LFA for the most up-to-date research information, or to volunteer for we know that some of these important research studies. hormones and environmental What is lupus? factors play 2 n Lupus is a chronic autoimmune disease that can damage any part of a role in who the body (skin, joints and/or organs inside the body). Chronic means develops that the signs and symptoms tend to persist longer than six weeks lupus. and often for many years. With good medical care, most people with lupus can lead a full life. n With lupus, something goes wrong with your immune system, which is the part of the body that fights off viruses, bacteria, and germs (“foreign invaders,” like the flu).
    [Show full text]
  • Tests for Autoimmune Diseases Test Codes 249, 16814, 19946
    Tests for Autoimmune Diseases Test Codes 249, 16814, 19946 Frequently Asked Questions Panel components may be ordered separately. Please see the Quest Diagnostics Test Center for ordering information. 1. Q: What are autoimmune diseases? A: “Autoimmune disease” refers to a diverse group of disorders that involve almost every one of the body’s organs and systems. It encompasses diseases of the nervous, gastrointestinal, and endocrine systems, as well as skin and other connective tissues, eyes, blood, and blood vessels. In all of these autoimmune diseases, the underlying problem is “autoimmunity”—the body’s immune system becomes misdirected and attacks the very organs it was designed to protect. 2. Q: Why are autoimmune diseases challenging to diagnose? A: Diagnosis is challenging for several reasons: 1. Patients initially present with nonspecific symptoms such as fatigue, joint and muscle pain, fever, and/or weight change. 2. Symptoms often flare and remit. 3. Patients frequently have more than 1 autoimmune disease. According to a survey by the Autoimmune Diseases Association, it takes up to 4.6 years and nearly 5 doctors for a patient to receive a proper autoimmune disease diagnosis.1 3. Q: How common are autoimmune diseases? A: At least 30 million Americans suffer from 1 or more of the 80 plus autoimmune diseases. On average, autoimmune diseases strike three times more women than men. Certain ones have an even higher female:male ratio. Autoimmune diseases are one of the top 10 leading causes of death among women age 65 and under2 and represent the fourth-largest cause of disability among women in the United States.3 Women’s enhanced immune system increases resistance to infection, but also puts them at greater risk of developing autoimmune disease than men.
    [Show full text]
  • Autoimmune Diseases
    POLICY BRIEFING Autoimmunity March 2016 of this damage the adrenal gland does not produce enough steroid hormones (primary adrenal insufficiency), resulting Key points in symptoms which include fatigue, muscle weakness, and a loss of appetite. This can be fatal if not recognised and • Autoimmunity involves a misdirection of the body’s treated, but treatment is relatively simple. immune system against its own tissues, causing a large • Grave’s disease – affecting the thyroid, Grave’s disease is number of diseases. one of the most common causes of hyperthyroidism. It • More than 80 autoimmune diseases have so far been results from the production of antibodies that mimic Thyroid identified: some affect only one tissue or organ, while Stimulating Hormone, which produces a false signal causing others are ‘systemic’ (affection multiple sites of the the thyroid gland to produce excessive thyroid hormone. body). Symptoms including insomnia, tremor, and hyperactivity. • Hundreds of thousands of individuals in the UK are • Type 1 diabetes – diabetes mellitus type 1 is a consequence of affected by autoimmunity. the autoimmune destruction of cells in the pancreas which • Most autoimmune diseases have very long-term effects produce insulin. Insulin is essential to control blood sugar on health, placing a large burden on the NHS and on levels and if left uncontrolled the disease can lead to serious national economies. complications, such as damage to the nerves, heart disease, • Current treatment aims to minimise symptoms and is and problems with the retina. Without adequate treatment often not curative. It is imperative that immunological type 1 diabetes would be fatal. research receives adequate investment in order to better • Crohn’s disease – a type of inflammatory bowel disease (IBD), understand these conditions so that we can open up new Crohn’s is a result of chronic inflammation of the lining of the therapeutic strategies.
    [Show full text]
  • Difficult-To-Diagnose Diabetes in a Patient Treated With
    García-Sáenz et al. Journal of Medical Case Reports (2018) 12:364 https://doi.org/10.1186/s13256-018-1925-3 CASE REPORT Open Access Difficult-to-diagnose diabetes in a patient treated with cyclophosphamide – the contradictory roles of immunosuppressant agents: a case report Manuel García-Sáenz1, Daniel Uribe-Cortés1, Claudia Ramírez-Rentería2 and Aldo Ferreira-Hermosillo2* Abstract Background: Cyclophosphamide may induce autoimmune diabetes through a decrease in suppressor T cells and increase of proinflammatory T helper type 1 response in animal models. In humans, this association is not as clear due to the presence of other risk factors for hyperglycemia, but it could be a precipitant for acute complications. Case presentation: A 31-year-old Mestizo-Mexican woman with a history of systemic lupus erythematosus presented with severe diabetic ketoacidosis, shortly after initiating a multi-drug immunosuppressive therapy. She did not meet the diagnostic criteria for type 1 or type 2 diabetes and had no family history of hyperglycemic states. She persisted with hyperglycemia and high insulin requirements until the discontinuation of cyclophosphamide. After this episode, she recovered her endogenous insulin production and the antidiabetic agents were successfully withdrawn. After 1 year of follow up she is still normoglycemic. Conclusion: Cyclophosphamide may be an additional risk factor for acute hyperglycemic crisis. Glucose monitoring could be recommended during and after this treatment. Keywords: Cyclophosphamide, Diabetic ketoacidosis, Lupus erythematosus, systemic Background effect of counterregulatory hormones, diabetic ketoacidosis Most patients with diabetes mellitus (DM) are classified (DKA) may occur [3]. into the commonly accepted groups: type 1 DM (T1DM), Cyclophosphamide (CY) is a cytotoxic chemotherapeutic type 2 DM, gestational DM, latent autoimmune diabetes of agent used in the treatment of hematological diseases.
    [Show full text]
  • Autoimmune Disease: Targeting IL-7 Reverses Type 1 Diabetes
    RESEARCH HIGHLIGHTS of IL-7R blockade. So they next AUTOIMMUNE DISEASE investigated the effects of IL-7 and IL-7R-targeted antibodies in T cells isolated from NOD mice. Targeting IL-7 reverses These studies suggested that two mechanisms are likely to mediate the effects of IL-7R blockade. First, IL-7 type 1 diabetes was shown to increase the number of interferon-γ-producing effector T cells, which are known to be Two recent studies published in the authors of both studies used IL-7 involved in the pathogenesis of type 1 PNAS suggest that blocking the receptor (IL-7R)-blocking antibodies diabetes, and this effect was reversed function of interleukin-7 (IL-7) using When IL-7R in the non-obese diabetic (NOD) by IL-7R-targeted antibodies. monoclonal antibodies could provide antibodies mouse model of type 1 diabetes. Second, IL-7R-targeted anti­bodies a disease-modifying approach in Administration of the antibodies increased the expression of pro- type 1 diabetes. The papers also show were (given by once- or twice-weekly injec- grammed cell death protein 1 (PD1), that modulation of effector T cells — administered tion) to pre-diabetic mice prevented a negative regulator of T cell activity T cells that can migrate to peripheral to mice onset of the disease and resulted in expressed on the surface of effector sites of inflammation — underlies the less infiltration of effector T cells T cells that is involved in immune therapeutic effects of targeting IL-7. with new- into pancreatic islets. When IL-7R tolerance (the process by which the Type 1 diabetes is an autoimmune onset type 1 antibodies were administered to immune system ignores self-antigens).
    [Show full text]
  • Nephrotic Syndrome in the Course of Type 1 Diabetes Mellitus And
    Case-based review Reumatologia 2020; 58, 5: 331–334 DOI: https://doi.org/10.5114/reum.2020.100105 Nephrotic syndrome in the course of type 1 diabetes mellitus and systemic lupus erythematosus with secondary antiphospholipid syndrome – diagnostic and therapeutic problems Aleksandra Graca, Dorota Suszek, Radosław Jeleniewicz, Maria Majdan Department of Rheumatology and Connective Tissue Diseases, Medical University of Lublin, Poland Abstract Nephrotic syndrome (NS) can be a symptom of many autoimmune, metabolic, or infectious diseases. Kidney involvement is often observed in the course of diabetes mellitus (DM) and systemic lupus erythematosus (SLE). The development of NS with coexisting SLE and DM generates serious diag- nostic problems. In this paper, the authors present diagnostic and therapeutic dilemmas in a pa- tient with long-lasting DM, SLE, and secondary antiphospholipid syndrome, in whom NS symptoms appeared. Histopathological examination of the kidney confirmed the diagnosis of lupus nephritis. Immunosuppressive and anticoagulant drugs were used. The authors demonstrated that the character of morphologic lesions in the kidney biopsy can help in diagnosis, nephropathy classification, and further therapeutic decisions, which are distinct in both diseases. Key words: nephrotic syndrome, diabetes mellitus type 1, systemic lupus erythematosus. Introduction Systemic lupus erythematosus is a chronic autoim- mune disease that is associated with disturbances of Nephrotic syndrome (NS) is a clinical condition chara- acquired and innate immunity caused by various envi- cterized by daily loss of protein in the urine > 3.5 g/ ronmental factors and genetic predispositions. Lupus 1.73 m²/day, hypoalbuminemia, hyperlipidemia, and the nephritis (LN) occurs in 35–75% of patients with SLE and presence of edema.
    [Show full text]
  • Therapeutics Bulletin
    Therapeutics Bulletin October 2018 Please see Important Safety Information throughout. Please see accompanying Prescribing Information, including Boxed Warning. Table of contents Introduction Introduction page 2 Diabetes is a complex disease that has the potential to negatively influence the health of patients if left untreated. Type 2 Diabetes and Cardiovascular Disease page 3 Currently, about 30 million people in the United States have diabetes (including about 7 million undiagnosed Introduction to Victoza® page 4 cases), which represents about 9.4% of the U.S. population. Approximately 90-95% of those cases are patients with LEADER Trial page 5 type 2 diabetes. Almost 34% of the population has pre- diabetes (based on elevated fasting glucose or A1C levels), Additional features page 10 meaning they are at risk for developing type 2 diabetes.1 Complications associated with type 2 diabetes can lead to Summary page 10 increased emergency room visits, hospitalizations, and even death.1 For these reasons, treatment of type 2 diabetes and References page 12 its associated complications is an important topic of study. Among other complications, patients with type 2 diabetes often experience cardiovascular disease (CVD). One therapy used to treat type 2 diabetes is Victoza® (liraglutide) injection 1.2 mg or 1.8 mg a human glucagon- PUBLISHER ASSISTANT ART DIRECTOR like peptide-1 (GLP-1) analog that was approved by the Gene Conselyea John Salesi U.S. Food and Drug Administration on January 25, 2010, WRITER/EDITOR PROJECT MANAGER as an adjunct to diet and exercise, to improve glycemic Jaelithe Russ Aubrey Feeley control in adults with type 2 diabetes.
    [Show full text]
  • 10 Chronic Urticaria As an Autoimmune Disease
    10 Chronic Urticaria as an Autoimmune Disease Michihiro Hide, Malcolm W. Greaves Introduction Urticaria is conventionally classified as acute, intermittent and chronic (Grea- ves 2000a). Acute urticaria which frequently involves an IgE-mediated im- munological mechanism, is common, its causes often recognised by the patient, and will not be considered further. Intermittent urticaria – frequent bouts of unexplained urticaria at intervals of weeks or months – will be dis- cussed here on the same basis as ‘ordinary’ chronic urticaria. The latter is conventionally defined as the occurrence of daily or almost daily whealing for at least six weeks. The etiology of chronic urticaria is usually obscure. The different clinical varieties of chronic urticaria will be briefly considered here, and attention will be devoted to a newly emerged entity – autoimmune chronic urticaria, since establishing this diagnosis has conceptual, prognostic and the- rapeutic implications. Contact urticaria and angioedema without urticaria will not be dealt with in this account. Classification of Chronic Urticaria The clinical subtypes of chronic urticaria are illustrated in the pie-chart of Fig. 1. The frequency of these subtypes is based upon the authors’ experience at the St John’s Institute of Dermatology in UK. Whilst there may well be mi- nor differences, it is likely that the frequency distribution of these subtypes will be essentially similar in most centres in Europe and North America (Grea- ves 1995, 2000b). However, our experience suggests that the incidence of angioedema, especially that complicated by ordinary chronic urticaria is sub- stantially lower in Japan and south Asian countries (unpublished observation). 310 Michihiro Hide and Malcolm W.
    [Show full text]